The effects of tolbutamide on lipoproteins, lipoprotein lipase and hormone-sensitive lipase

Diabetes Research and Clinical Practice

Volumn 46, Issue 2, 1999, Pages 99-108

  Agardh, C D ^a   Bjorgell P ^b   Nilsson Ehle, P ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Atherosclerosis; Hormone sensitive lipase; Lipoprotein lipase; Lipoprotein metabolism; Tolbutamide

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; TOLBUTAMIDE;

ADULT; AGED; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT;

ADIPOCYTES; AGED; CHOLESTEROL ESTERASE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPOLYSIS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; MIDDLE AGED; PHOSPHORYLATION; TOLBUTAMIDE;

EID: 0345363291     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(99)00088-1     Document Type: Article

References (50)

1. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease in the Framingham study. J. Am. Med. Assoc. 241:1979;2035-2038.
2. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study. Br. Med. J. 287:1983;867-870.
3. Pyörälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic review. Diabetes Metab. Rev. 3:1993;463-524.
4. J. Stamler, O. Vaccaro, J. Neaton, D. Wentworth for the Multiple Risk Factor Intervention Trial Research Group, Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial, Diabetes Care 16 (1993) 434-444.
5. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med. 329 (1993) 977-986.
6. Barrett-Connor E., Witztum J.L., Holdbrook M. A community study of high density lipoproteins in adult non-insulin-dependent diabetics. Am. J. Epidemiol. 117:1983;186-192.
7. Walden C.E., Knopp R.H., Wahl P.W., Beach K.W., Strandness E. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N. Engl. J. Med. 311:1984;953-959.
8. Lehto S., Rönnemaa T., Haffner S.M., Pyörälä K., Kallio V., Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 46:1997;1354-1359.
9. Klimt C.R., Knatterud G.L., Meinert C.L., Prout T.E. The University Group Diabetes Program: a study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline characteristics. II. Mortality results. Diabetes. 19(Suppl. 2):1970;474-830.
10. Anonymous, A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide, Diabetes 25 (1970) 1129-1153.
11. Schor S. The University Group Diabetes Program: a statistician looks at the mortality results. J. Am. Med. Assoc. 217:1971;1673-1675.
12. Seltzer H. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes. 21:1972;976-979.
13. Kolata G. Controversy over study of diabetes drugs continues for nearly a decade. Science. 203:1979;986-990.
14. Kilo C., Miller L., Williamson J. The crux of the UGDP: spurious results and biologically inappropriate data analysis. Diabetologia. 18:1980;179-185.
15. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998) 837-853.
16. World Health Organization, Diabetes mellitus: Report of a WHO study group, Technical Report Series 127, WHO, Geneva, 1985.
17. Roeslau P., Bernt E., Gruber W. Enzymatische Bestimmungen des Gesamt: cholesterins in serum. J. Klin. Chem. Klin. Biochem. 12:1974;226-229.
18. Wahlefeld A.W. Triglyceride determination after enzymatic hydrolysis. Bergmayer H.U. Methods of Enzymatic Analysis. 2nd edn:1974;1834 Academic Press, New York.
19. Danielsson B., Ekman R., Fex G., Johansson B.G., Kristensson H., Nilsson-Ehle P., Wadstein J. Changes in plasma high density lipoproteins in chronic male alcoholics during and after abuse. Scand. J. Clin. Lab. Invest. 38:1978;113-119.
20. Friedewald W.T., Levy R.I., Fredrikson D.S. Estimation of the concentration of low density lipoprotein cholesterol without use of the preparative ultra-centrifuge. Clin. Chem. 18:1972;449-502.
21. Nilsson-Ehle P., Ekman R. Rapid, simple and specific assays for lipoprotein lipase and hepatic lipase. Artery. 3:1977;194-209.
22. Carlsson L.A., Rössner S. A methodological study of an intravenous fat tolerance test with Intralipid emulsion. Scand. J. Clin. Lab. Invest. 29:1972;243-249.
23. Björgell P., Rosberg S., Isaksson O., Belfrage P. The antilipolytic, insulin-like effect of growth hormone is caused by a net decrease of hormone-sensitive lipase phosphorylation. Endocrinology. 115:1984;1151-1156.
24. Nilsson N.Ö., Belfrage P. Effects of acetate, acetaldehyde, and ethanol on lipolysis in isolated rat adipocytes. J. Lipid Res. 19:1978;737-741.
25. Moody A.J., Stan M.A., Stan M., Gliemann J. A simple free fat cell bioassay for insulin. Horm. Metab. Res. 6:1974;12-16.
26. Laurell S., Tibbling G. An enzymatic fluorometric micromethod for the determination of glycerol. Clin. Chim. Acta. 13:1966;317-322.
27. Nilsson N.Ö., Belfrage P. Release of free fatty acids from adipocytes measured continuously by pH-stat titration. J. Lipid Res. 20:1979;557-560.
28. Nilsson-Ehle P. Human lipoprotein lipase activity: comparison of assay methods. Clin. Chim. Acta. 54:1974;283-291.
29. Garfinkel A.S., Nilsson-Ehle P., Schotz M.C. Regulation of lipoprotein lipase: induction by insulin. Biochim. Biophys. Acta. 424:1976;264-273.
30. Gerich J.E. Oral hypoglycemic agents. N. Engl. J. Med. 321:1989;1231-1245.
31. + channels in cardiac muscle. Nature. 305:1983;147-148.
32. + channels in arterial smooth muscle. Science. 245:1989;177-180.
33. Smits P., Thien T. Cardiovascular effects of sulphonylurea derivates. Implications for the treatment of NIDDM? Diabetologia. 38:1995;116-121.
34. Leibowitz G., Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia. 39:1996;503-514.
35. Kolterman O.G., Gray R.S., Shapiro G., Scarlett J.A., Griffin J., Olefsky J.M. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 33:1984;346-354.
36. Bolinder J., Ostman J., Arner P. Reversal of insulin resistance in adipose tissue of noninsulin-dependent diabetics by treatment with diet and sulphonylurea. Acta Endocrinol. 108:1985;85-90.
37. Chang A.Y., Wyse B.M., Gilchrist B.J. Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipocyte tissue of C57BL/6J-ob/ob and -+/?mice. Diabetes. 32:1983;839-845.
38. Maloff B.L., Lockwood D.H. In vitro effects of a sulfonylurea on insulin action in adipocytes. Potentiation of insulin-stimulated hexose transport. J. Clin. Invest. 68:1981;85-90.
39. Altan N., Altan V.M., Mikolay L., Larner J., Schwartz C.F. Insulin-like and insulin-enhancing effects of the sulfonylurea glyburide on rat adipose glycogen synthase. Diabetes. 34:1985;281-286.
40. Melander A., Sartor G., Wåhlin E., Scherstén B., Bitzén P.O. Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus. Br. Med. J. 1:1978;142-144.
41. Sobenin I.A., Maksumova M.A., Slavina E.S., Balabolkin M.I., Orekhov A.N. Sulfonylureas induce cholesterol accumulation in cultured human intimal cells and macrophages. Atherosclerosis. 105:1994;159-163.
42. Lopes-Virella M.F., Stone P.G., Colwell J.A. Serum high density lipoprotein in diabetic patients. Diabetologia. 13:1977;285-291.
43. Lisch H.J., Sailer S. Lipoprotein patterns in diet, sulphonylurea, and insulin treated diabetics. Diabetologia. 20:1981;118-122.
44. Huupponen R.K., Viikari J.S., Saarimaa H. Correlation of serum lipids with diabetes control in sulfonylurea-treated diabetic patients. Diabetes Care. 7:1984;575-578.
45. Calvert G.D., Graham J.J., Mannik T., Wise P.H., Yeates R.A. Effects of therapy on plasma-high-density-lipoprotein-cholesterol concentration in diabetes mellitus. Lancet. 2:1978;66-68.
46. Taskinen M.R., Beltz W.F., Harper I. et al. Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy. Diabetes. 35:1986;1268-1277.
47. Moorhouse J.A. A comparison of the effects of tolazamide and tolbutamide upon blood glucose and serum insulin and lipid levels in diabetic subjects. Can. Med. Assoc. J. 96:1967;536-539.
48. Kennedy A.L., Lappin T.R., Lavery T.D., Hadden D.R., Weaver J.A., Montgomery D.A. Relation of high-density lipoprotein cholesterol concentration to type of diabetes and its control. Br. Med. J. 2:1978;1191-1194.
49. Greenfield M.S., Doberne L., Rosenthal M., Vreman H.J., Reaven G.M. Lipid metabolism in non-insulin-dependent diabetes mellitus: effect of glipizide therapy. Arch. Intern. Med. 142:1982;1498-1500.
50. Kasim S.E., LeBoeuf R.C., Rockett M.J., Page J., Keyser A.J. The effects of oral agents or insulin treatments on the plasma lipoproteins and the plasma lipoprotein lipase activator in diabetic patients. Horm. Metab. Res. 18:1986;190-193.